Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsDiscoidin Domain Receptors: Potential Actors and Targets in CancerBosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.Type I collagen aging impairs discoidin domain receptor 2-mediated tumor cell growth suppressionDiscoidin domain receptors: a proteomic portrait.Discoidin domain receptor 2 signaling networks and therapy in lung cancer.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.Progression inference for somatic mutations in cancer.NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.Lung Cancer Biomarkers.Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.Non-small-cell lung cancer.
P2860
Q26741318-40495409-F795-4455-9157-935263B1A680Q26751157-DCA00DD1-77B3-44A2-9C7C-B6828DD65B5BQ34026441-E8C4C28D-EDC7-4B3A-A18F-C66167AB3A53Q36430737-99B9D789-164D-4E42-9EAD-5D68CC497B2CQ37295230-15A36EEA-E9CF-4FE1-83A4-895087DEF7ACQ38202550-88364E1C-5FE8-474C-B391-618854D8491AQ38211796-4D8CB8CA-DFB7-4FCC-93DA-5B6853021A2AQ38245669-549BD559-11CF-4613-8EFA-74D6541E2998Q38756969-49DFDAD2-B62B-4471-967F-680DC50FF831Q38768576-C665D24C-6601-42E3-99B0-8C43EE619B5BQ38793244-E82388ED-B7D5-4D73-9516-2D7E5AF02BBDQ38849817-7BF6EE41-1142-4736-A8FA-C995B3118C02Q39027394-D103B214-1EEB-47A7-A469-A2B1AC71240EQ41108643-F802DFD5-EEF2-45D5-B0C8-806A93C9BF7EQ48333251-7848079C-BDA4-49E6-9DAC-0D96486DDD03Q50005441-6655F9B5-6B66-46C8-9107-C78C4134899FQ50351356-2575A786-61F5-481F-B621-FC98CCA23C8DQ51021428-1A3F654F-4DB3-497B-88D6-E24FDACC1D2B
P2860
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@en
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@nl
type
label
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@en
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@nl
prefLabel
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@en
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@nl
P2093
P2860
P50
P1476
Acquired resistance to dasatin ...... ekeeper mutation and NF1 loss.
@en
P2093
Adam J Bass
Austin M Dulak
Brittany A Woods
Chunxiao Xu
Ellen M Beauchamp
Nathanael S Gray
Peter S Hammerman
P2860
P304
P356
10.1158/1535-7163.MCT-13-0817
P577
2013-12-02T00:00:00Z